Synonym
NXN-188; NXN188; NXN 188
IUPAC/Chemical Name
4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid
InChi Key
JWNUBAIGCVTLMJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H36N2O6/c1-27(7-6-26(32)33,22-2-4-24(30)20(16-22)18-28-8-12-34-13-9-28)23-3-5-25(31)21(17-23)19-29-10-14-35-15-11-29/h2-5,16-17,30-31H,6-15,18-19H2,1H3,(H,32,33)
SMILES Code
CC(C1=CC=C(O)C(CN2CCOCC2)=C1)(C3=CC=C(O)C(CN4CCOCC4)=C3)CCC(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
484.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J. NXN-188, a
selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release
in preclinical migraine models. Cephalalgia. 2013 Jan;33(2):87-100. doi:
10.1177/0333102412466967. Epub 2012 Nov 15. PMID: 23155193.
2: Vaughan D, Speed J, Medve R, Andrews JS. Safety and pharmacokinetics of
NXN-188 after single and multiple doses in five phase I, randomized, double-
blind, parallel studies in healthy adult volunteers. Clin Ther. 2010
Jan;32(1):146-60. doi: 10.1016/j.clinthera.2010.01.006. PMID: 20171420.
3: Hougaard A, Hauge AW, Guo S, Tfelt-Hansen P. The nitric oxide synthase
inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of
migraine with aura: A randomized, double-blind, placebo-controlled cross-over
study. Scand J Pain. 2013 Jan 1;4(1):48-52. doi: 10.1016/j.sjpain.2012.08.002.
PMID: 29913885.
4: Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M,
Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P. Emerging treatment for
chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012
Sep;17(3):393-406. doi: 10.1517/14728214.2012.709846. Epub 2012 Aug 3. PMID:
22862686.
